Checkpoint Inhibitor

radiation therapy (RT) for Cancer

Waitlist Available
Led By Michael D Chuong, MD
Research Sponsored by Baptist Health South Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Life expectancy of .12 weeks as estimated by the treating physician
Be older than 18 years old
Must not have
Be younger than 18 years old
Screening 3 weeks
Treatment Varies
Follow Upthrough study completion, an average of 1 year
Awards & highlights
No Placebo-Only Group

Study Summary

This trial is testing a new cancer treatment in patients who have not responded well to other treatments.

Eligible Conditions
  • Metastatic Cancer

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
Your doctor predicts that you have less than 12 weeks to live.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in overall response rate according to RECIST 1.1 criteria
Secondary outcome measures
Change in immune-related response criteria
Duration of response
Measure the number of progression free survival
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: radiation therapy (RT)Experimental Treatment1 Intervention
RT for all subjects will consist of treating one tumor of the treating physician's preference (40 Gy in 5 fractions), and after a 1-week interval during which Immune checkpoint inhibitor (ICI) is continued alone, RT will be given to a second and separate tumor (30 Gy in 5 fractions).
First Studied
Drug Approval Stage
How many patients have taken this drug
Radiation Therapy
Completed Phase 3

Find a site

Who is running the clinical trial?

Baptist Health South FloridaLead Sponsor
47 Previous Clinical Trials
7,734 Total Patients Enrolled
Viewray Inc.Industry Sponsor
11 Previous Clinical Trials
1,052 Total Patients Enrolled
Michael D Chuong, MDPrincipal Investigator
Miami Cancer Institute (MCI) at Baptist Health, Inc.

Media Library

Immune Checkpoint Inhibitor (Checkpoint Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04376502 — N/A
Cancer Research Study Groups: radiation therapy (RT)
Cancer Clinical Trial 2023: Immune Checkpoint Inhibitor Highlights & Side Effects. Trial Name: NCT04376502 — N/A
Immune Checkpoint Inhibitor (Checkpoint Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04376502 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are potential enrollees still accepted for this experiment?

"According to this research is currently recruiting participants, having been first announced on April 8th 2020 and last modified on November 8th 2022."

Answered by AI

How many participants will be included in this research endeavor?

"Affirmative. has the information that this research is presently looking for participants, with a first post date of April 8th 2020 and an edit on November 8th 2022; 52 individuals need to be recruited at one medical facility."

Answered by AI
~0 spots leftby Nov 2023